세계의 바이오의약품 CDMO 시장 - 규모, 점유율, 동향 분석 보고서 : 유형별, 제품별, 서비스별, 공급원별, 워크플로우별, 치료 영역별, 최종 용도별, 지역별 부문 예측(2025-2033년)

Biopharmaceutical CDMO Market Summary

The global biopharmaceutical contract development and manufacturing organization market size was estimated at USD 25.1 billion in 2024 and is projected to reach USD 56.6 billion by 2033, growing at a CAGR of 9.55% from 2025 to 2033. The industry is driven by increasing demand for biologics, biosimilars, and advanced therapies.

Besides, rising demand for outsourcing services, growing expansion of large product pipeline, and increasing cost effectiveness within CDMO services have led most biopharmaceutical manufacturers to outsource their production capabilities. Most biopharmaceutical companies are developing biologics & biosimilars due to continuous demand for targeted, effective, and personalized therapies, as these offer higher efficacy, reduced side effects, and the ability to address complex & chronic diseases such as cancer, autoimmune disorders, and rare genetic conditions. Besides, the industry has witnessed new growth opportunities due to specialized CDMOs offering greater speed-to-market, expanding patent expiration, and rising need for blockbuster drugs, creating a strong pipeline for biologics and biosimilars, further contributing to market growth. In addition, growing advancements in biotechnology have further lowered production costs and risks. Thus, biologics are currently prioritized for clinical value, commercial potential, and long-term growth prospects.

Biopharmaceuticals manufacturing will be recognized as one of the leading 10 revenue generators in the coming years. Currently, most of the small molecule makes up to 90% of drugs on the market and continue to be the primary active substance in the pharmaceutical industry; however, companies are increasingly shifting their focus to manufacturing and developing highly profitable, highly complex large molecules known as biologics. This has led biopharmaceutical companies to necessitate collaboration with external partners capable of managing advanced manufacturing processes to continuously develop new products to meet the increasing consumer demand, which in turn is anticipated to surge CDMO services. For instance, the International Federation of Pharmaceutical Manufacturers & Associations mentioned that the biopharmaceutical R&D spending is expected to grow to USD 213 million by 2025, owing to the growing demand for biopharmaceutical products. In addition, an expanding number of drug pipelines has significantly contributed to market growth.

Global Biopharmaceutical CDMO Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global biopharmaceutical contract development and manufacturing organization (CDMO) market report based on type, product, service, source, workflow, therapeutic area, end use, and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• API
• Finished Drug Product
  • Oral Solid Dose
  • Semi-Solid Dose
  • Liquid Dose
  • Others
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Biologics
  • Monoclonal antibodies (mAbs)
  • Recombinant proteins & enzymes
  • Vaccines
  • Cell & Gene Therapies
  • Nucleic acid Therapeutics
  • Others
• Biosimilars
• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Contract Development
  • Cell Line Development
  • Process Development
• Upstream
• Downstream
  • Analytical Testing & Method Validation
  • Scale-Up & Tech Transfer
• Contract Manufacturing
  • API Manufacturing
  • Finished Drug Products Manufacturing
• Packaging and Labelling
• Regulatory Affairs
• Logistics & Storage
• Others
• Source Outlook (Revenue, USD Million, 2021 - 2033)
• Mammalian
• Microbial
• Workflow Outlook (Revenue, USD Million, 2021 - 2033)
• Clinical
• Commercial
• Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
• Oncology
• Infectious Diseases
• Neurological Disorders
• Cardiovascular Disease
• Metabolic Disorders
• Autoimmune Diseases
• Respiratory Diseases
• Ophthalmology
• Gastrointestinal Disorders
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Large Pharma & Biotech Companies
• Small & Mid-sized Pharma & Biotech Companies
• Academic Research & Government Institutes
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
  • Qatar
  • Oman

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Product
  • 1.2.3. Service
  • 1.2.4. Source
  • 1.2.5. Workflow
  • 1.2.6. Therapeutic Area
  • 1.2.7. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Top-Down Analysis
  • 1.7.3. Botton-Up Approach
  • 1.7.4. Multivariate Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Biopharmaceutical Contract Development and Manufacturing Organization Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising Demand for Biologics & Advanced Therapy
    • 3.2.1.2. Rising Investment In R&D
    • 3.2.1.3. Growing Biopharmaceutical Industry
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Compliance Issues While Outsourcing
    • 3.2.2.2. Changing Scenarios In Developing Countries
• 3.3. Technology Landscape
• 3.4. Pricing Model Analysis
• 3.5. Tariff Impact Analysis
• 3.6. Value Chain Analysis
  • 3.6.1. Supply Trends
  • 3.6.2. Demand Trends
• 3.7. Market Analysis Tools
  • 3.7.1. Porter's Five Force Analysis
  • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Biopharmaceutical Contract Development and Manufacturing Organization Market: Type Estimates & Trend Analysis

• 4.1. Biopharmaceutical Contract Development and Manufacturing Organization Market, By Type: Segment Dashboard
• 4.2. Biopharmaceutical Contract Development and Manufacturing Organization Market, By Type: Movement Analysis
• 4.3. Biopharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Type, 2021 - 2033 (USD Million)
• 4.4. API
  • 4.4.1. API Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Finished Drug Product
  • 4.5.1. Finished Drug Product Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.2. Oral Solid Dose
    • 4.5.2.1. Oral Solid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.3. Semi-Solid Dose
    • 4.5.3.1. Semi-Solid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.4. Liquid Dose
    • 4.5.4.1. Liquid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.5. Others
    • 4.5.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Biopharmaceutical Contract Development and Manufacturing Organization Market: Product Estimates & Trend Analysis

• 5.1. Biopharmaceutical Contract Development and Manufacturing Organization Market, By Product: Segment Dashboard
• 5.2. Biopharmaceutical Contract Development and Manufacturing Organization Market, By Product: Movement Analysis
• 5.3. Biopharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Product, 2021 - 2033 (USD Million)
• 5.4. Biologics
  • 5.4.1. Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.2. Monoclonal Antibodies (mAbs)
    • 5.4.2.1. Monoclonal antibodies (mAbs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.3. Recombinant Proteins & Enzymes
    • 5.4.3.1. Recombinant Proteins & Enzymes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.4. Vaccines
    • 5.4.4.1. Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.5. Cell & Gene Therapies
    • 5.4.5.1. Cell & Gene Therapies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.6. Nucleic acid Therapeutics
    • 5.4.6.1. Nucleic Acid Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.7. Others
    • 5.4.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Biosimilars
  • 5.5.1. Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Biopharmaceutical Contract Development and Manufacturing Organization Market: Service Estimates & Trend Analysis

• 6.1. Biopharmaceutical Contract Development and Manufacturing Organization Market, By Service: Segment Dashboard
• 6.2. Biopharmaceutical Contract Development and Manufacturing Organization Market, By Service: Movement Analysis
• 6.3. Biopharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
• 6.4. Contract Development
  • 6.4.1. Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.2. Cell Line Development
    • 6.4.2.1. Cell Line Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.3. Process Development & Optimization
    • 6.4.3.1. Process Development & Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3.2. Upstream
      • 6.4.3.2.1. Upstream Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3.3. Downstream
      • 6.4.3.3.1. Downstream Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.4. Analytical Testing & Method Validation
    • 6.4.4.1. Analytical Testing & Method Validation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.5. Scale-up & Tech Transfer
    • 6.4.5.1. Scale-up & Tech Transfer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Contract Manufacturing
  • 6.5.1. Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.2. API Manufacturing
    • 6.5.2.1. API Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.3. Finished drug products Manufacturing
    • 6.5.3.1. Finished drug products Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Packaging and Labelling
  • 6.6.1. Packaging and Labelling Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Regulatory Affairs
  • 6.7.1. Regulatory Affairs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Logistics & Storage
  • 6.8.1. Logistics & Storage Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.9. Others
  • 6.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Biopharmaceutical Contract Development and Manufacturing Organization Market: Source Estimates & Trend Analysis

• 7.1. Biopharmaceutical Contract Development and Manufacturing Organization Market, By Source: Segment Dashboard
• 7.2. Biopharmaceutical Contract Development and Manufacturing Organization Market, By Source: Movement Analysis
• 7.3. Biopharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Source, 2021 - 2033 (USD Million)
• 7.4. Mammalian
  • 7.4.1. Mammalian Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Microbial
  • 7.5.1. Microbial Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Biopharmaceutical Contract Development and Manufacturing Organization Market: Workflow Estimates & Trend Analysis

• 8.1. Biopharmaceutical Contract Development and Manufacturing Organization Market, By Workflow: Segment Dashboard
• 8.2. Biopharmaceutical Contract Development and Manufacturing Organization Market, By Workflow: Movement Analysis
• 8.3. Biopharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Workflow, 2021 - 2033 (USD Million)
• 8.4. Clinical
  • 8.4.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Commercial
  • 8.5.1. Commercial Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Biopharmaceutical Contract Development and Manufacturing Organization Market: Therapeutic Area Estimates & Trend Analysis

• 9.1. Biopharmaceutical Contract Development and Manufacturing Organization Market, By Therapeutic Area: Segment Dashboard
• 9.2. Biopharmaceutical Contract Development and Manufacturing Organization Market, By Therapeutic Area: Movement Analysis
• 9.3. Biopharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Therapeutic Area, 2021 - 2033 (USD Million)
• 9.4. Oncology
  • 9.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.5. Infectious Diseases
  • 9.5.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.6. Neurological Disorders
  • 9.6.1. Neurological Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.7. Cardiovascular Disease
  • 9.7.1. Cardiovascular Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.8. Metabolic Disorders
  • 9.8.1. Metabolic Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.9. Autoimmune Diseases
  • 9.9.1. Autoimmune Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.10. Respiratory Diseases
  • 9.10.1. Respiratory Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.11. Ophthalmology
  • 9.11.1. Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.12. Gastrointestinal Disorders
  • 9.12.1. Gastrointestinal Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.13. Others
  • 9.13.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Biopharmaceutical Contract Development and Manufacturing Organization Market: End Use Estimates & Trend Analysis

• 10.1. Biopharmaceutical Contract Development and Manufacturing Organization Market, By End Use: Segment Dashboard
• 10.2. Biopharmaceutical Contract Development and Manufacturing Organization Market, By End Use: Movement Analysis
• 10.3. Biopharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
• 10.4. Large Pharma & Biotech Companies
  • 10.4.1. Large Pharma & Biotech Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 10.5. Small & Mid-sized Pharma & Biotech Companies
  • 10.5.1. Small & Mid-sized Pharma & Biotech Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 10.6. Academic Research & Government Institutes
  • 10.6.1. Academic Research & Government Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 11. Biopharmaceutical Contract Development And Manufacturing Organization Market: Regional Estimates & Trend Analysis

• 11.1. Regional Market Dashboard
• 11.2. Regional Market Share Analysis, 2024 & 2033
• 11.3. North America
  • 11.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 11.3.2. U.S
    • 11.3.2.1. Key Country Dynamics
    • 11.3.2.2. Competitive Scenario
    • 11.3.2.3. Regulatory Framework
    • 11.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 11.3.3. Canada
    • 11.3.3.1. Key Country Dynamics
    • 11.3.3.2. Competitive Scenario
    • 11.3.3.3. Regulatory Framework
    • 11.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 11.3.4. Mexico
    • 11.3.4.1. Key Country Dynamics
    • 11.3.4.2. Competitive Scenario
    • 11.3.4.3. Regulatory Framework
    • 11.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 11.4. Europe
  • 11.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 11.4.2. UK
    • 11.4.2.1. Key Country Dynamics
    • 11.4.2.2. Competitive Scenario
    • 11.4.2.3. Regulatory Framework
    • 11.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 11.4.3. Germany
    • 11.4.3.1. Key Country Dynamics
    • 11.4.3.2. Competitive Scenario
    • 11.4.3.3. Regulatory Framework
    • 11.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 11.4.4. France
    • 11.4.4.1. Key Country Dynamics
    • 11.4.4.2. Competitive Scenario
    • 11.4.4.3. Regulatory Framework
    • 11.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 11.4.5. Italy
    • 11.4.5.1. Key Country Dynamics
    • 11.4.5.2. Competitive Scenario
    • 11.4.5.3. Regulatory Framework
    • 11.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 11.4.6. Spain
    • 11.4.6.1. Key Country Dynamics
    • 11.4.6.2. Competitive Scenario
    • 11.4.6.3. Regulatory Framework
    • 11.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 11.4.7. Denmark
    • 11.4.7.1. Key Country Dynamics
    • 11.4.7.2. Competitive Scenario
    • 11.4.7.3. Regulatory Framework
    • 11.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 11.4.8. Sweden
    • 11.4.8.1. Key Country Dynamics
    • 11.4.8.2. Competitive Scenario
    • 11.4.8.3. Regulatory Framework
    • 11.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 11.4.9. Norway
    • 11.4.9.1. Key Country Dynamics
    • 11.4.9.2. Competitive Scenario
    • 11.4.9.3. Regulatory Framework
    • 11.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 11.5. Asia Pacific
  • 11.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 11.5.2. Japan
    • 11.5.2.1. Key Country Dynamics
    • 11.5.2.2. Competitive Scenario
    • 11.5.2.3. Regulatory Framework
    • 11.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 11.5.3. China
    • 11.5.3.1. Key Country Dynamics
    • 11.5.3.2. Competitive Scenario
    • 11.5.3.3. Regulatory Framework
    • 11.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 11.5.4. India
    • 11.5.4.1. Key Country Dynamics
    • 11.5.4.2. Competitive Scenario
    • 11.5.4.3. Regulatory Framework
    • 11.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 11.5.5. Australia
    • 11.5.5.1. Key Country Dynamics
    • 11.5.5.2. Competitive Scenario
    • 11.5.5.3. Regulatory Framework
    • 11.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 11.5.6. Thailand
    • 11.5.6.1. Key Country Dynamics
    • 11.5.6.2. Competitive Scenario
    • 11.5.6.3. Regulatory Framework
    • 11.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 11.5.7. South Korea
    • 11.5.7.1. Key Country Dynamics
    • 11.5.7.2. Competitive Scenario
    • 11.5.7.3. Regulatory Framework
    • 11.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 11.6. Latin America
  • 11.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 11.6.2. Brazil
    • 11.6.2.1. Key Country Dynamics
    • 11.6.2.2. Competitive Scenario
    • 11.6.2.3. Regulatory Framework
    • 11.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 11.6.3. Argentina
    • 11.6.3.1. Key Country Dynamics
    • 11.6.3.2. Competitive Scenario
    • 11.6.3.3. Regulatory Framework
    • 11.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 11.7. MEA
  • 11.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 11.7.2. South Africa
    • 11.7.2.1. Key Country Dynamics
    • 11.7.2.2. Competitive Scenario
    • 11.7.2.3. Regulatory Framework
    • 11.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 11.7.3. UAE
    • 11.7.3.1. Key Country Dynamics
    • 11.7.3.2. Competitive Scenario
    • 11.7.3.3. Regulatory Framework
    • 11.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 11.7.4. Saudi Arabia
    • 11.7.4.1. Key Country Dynamics
    • 11.7.4.2. Competitive Scenario
    • 11.7.4.3. Regulatory Framework
    • 11.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 11.7.5. Kuwait
    • 11.7.5.1. Key Country Dynamics
    • 11.7.5.2. Competitive Scenario
    • 11.7.5.3. Regulatory Framework
    • 11.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 11.7.6. Qatar
    • 11.7.6.1. Key Country Dynamics
    • 11.7.6.2. Competitive Scenario
    • 11.7.6.3. Regulatory Framework
    • 11.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 11.7.7. Oman
    • 11.7.7.1. Key Country Dynamics
    • 11.7.7.2. Competitive Scenario
    • 11.7.7.3. Regulatory Framework
    • 11.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 12. Competitive Landscape

• 12.1. Key Participant Categorization
  • 12.1.1. Market Leaders
  • 12.1.2. Emerging Players
• 12.2. Market Share/Assessment Analysis, 2024 (Heat Map Analysis)
• 12.3. Company Profiles
  • 12.3.1. Lonza Group
    • 12.3.1.1. Company Overview
    • 12.3.1.2. Financial Performance
    • 12.3.1.3. Service Benchmarking
    • 12.3.1.4. Strategic Initiatives
  • 12.3.2. Thermo Fisher Scientific
    • 12.3.2.1. Company Overview
    • 12.3.2.2. Financial Performance
    • 12.3.2.3. Service Benchmarking
    • 12.3.2.4. Strategic Initiatives
  • 12.3.3. Catalent Pharma Solutions
    • 12.3.3.1. Company Overview
    • 12.3.3.2. Financial Performance
    • 12.3.3.3. Service Benchmarking
    • 12.3.3.4. Strategic Initiatives
  • 12.3.4. Samsung Biologics
    • 12.3.4.1. Company Overview
    • 12.3.4.2. Financial Performance
    • 12.3.4.3. Service Benchmarking
    • 12.3.4.4. Strategic Initiatives
  • 12.3.5. WuXi Biologics / WuXi AppTec
    • 12.3.5.1. Company Overview
    • 12.3.5.2. Financial Performance
    • 12.3.5.3. Service Benchmarking
    • 12.3.5.4. Strategic Initiatives
  • 12.3.6. Boehringer Ingelheim (Biopharma CDMO)
    • 12.3.6.1. Company Overview
    • 12.3.6.2. Financial Performance
    • 12.3.6.3. Service Benchmarking
    • 12.3.6.4. Strategic Initiatives
  • 12.3.7. Fujifilm Diosynth Biotechnologies
    • 12.3.7.1. Company Overview
    • 12.3.7.2. Financial Performance
    • 12.3.7.3. Service Benchmarking
    • 12.3.7.4. Strategic Initiatives
  • 12.3.8. Charles River Laboratories
    • 12.3.8.1. Company Overview
    • 12.3.8.2. Financial Performance
    • 12.3.8.3. Service Benchmarking
    • 12.3.8.4. Strategic Initiatives
  • 12.3.9. AGC Biologics
    • 12.3.9.1. Company Overview
    • 12.3.9.2. Financial Performance
    • 12.3.9.3. Service Benchmarking
    • 12.3.9.4. Strategic Initiatives
  • 12.3.10. Siegfried Holding
    • 12.3.10.1. Company Overview
    • 12.3.10.2. Financial Performance
    • 12.3.10.3. Service Benchmarking
    • 12.3.10.4. Strategic Initiatives
  • 12.3.11. Recipharm
    • 12.3.11.1. Company Overview
    • 12.3.11.2. Financial Performance
    • 12.3.11.3. Service Benchmarking
    • 12.3.11.4. Strategic Initiatives
  • 12.3.12. Millipore Sigma (Merck KGaA)
    • 12.3.12.1. Company Overview
    • 12.3.12.2. Financial Performance
    • 12.3.12.3. Service Benchmarking
    • 12.3.12.4. Strategic Initiatives
  • 12.3.13. Biocon Biologics
    • 12.3.13.1. Company Overview
    • 12.3.13.2. Financial Performance
    • 12.3.13.3. Service Benchmarking
    • 12.3.13.4. Strategic Initiatives
  • 12.3.14. Sandoz
    • 12.3.14.1. Company Overview
    • 12.3.14.2. Financial Performance
    • 12.3.14.3. Service Benchmarking
    • 12.3.14.4. Strategic Initiatives
  • 12.3.15. Rentschler Biopharma SE
    • 12.3.15.1. Company Overview
    • 12.3.15.2. Financial Performance
    • 12.3.15.3. Service Benchmarking
    • 12.3.15.4. Strategic Initiatives